Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Kymera Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update KT-474/SAR444656 Phase 2 trials for both hidradenitis suppurativa and atopic dermatitis planned to start in 4Q23 by partner Sanofi Phase 1 oncology trials for KT-253 , KT-333 , and KT-413 degraders ongoing, with clinical updates planned for later in 2023 June 30, 2023 cash balance approximately $472 million, with cash runway into second half of 2025 Company to hold quarterly results call and webcast at 8:30 a.m. ET"
02/23/2023 8-K Quarterly results
Docs: "Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 in 2023 Phase 1 trials for STAT3 and IRAKIMiD degraders ongoing, with data evaluating clinical activity expected to be shared in 2023 Phase 1 clinical trial for MDM2 degrader expected to be initiated in early 2023 Year-end 2022 cash balance of approximately $560 million with cash runway into second half of 2025 Company to hold quarterly results call at 8:30 a.m. ET"
08/09/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
Docs: "Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring Clinical trials initiated for STAT3 and IRAKIMiD oncology programs Pre-clinical data presented at AACR on first-in-class MDM2 degrader, KT-253, highlighting the potential benefit of degradation over inhibition and broader clinical opportunities; IND filing planned for 2H22 March 31, 2022 cash balance of approximately $523 million, providing cash runway into 2025 Company to hold quarterly results call at 8am EST"
02/24/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in blood and up to 97% inhibition of cytokines FDA clearance of Investigational New Drug Application for first-in-class STAT3 degrader, KT-333 R&D Day Webinar scheduled for December 16, 2021, with first disclosures of KT-474 Multiple Ascending Dose data, new degrader programs in development and new platform expansions"
08/06/2021 8-K Quarterly results
Docs: "Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism"
05/06/2021 8-K Quarterly results
Docs: "Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021"
03/11/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "ompleted initial public offering . In August 2020, Kymera closed an upsized IPO of 9,987,520 of its common shares, including the exercise in full of the underwriters’ option to purchase an additional 1,302,720 common shares, at a public offering price of $20.00 per share. Concurrent with the IPO, Kymera announced the sale of 676,354 common shares at the public offering price per share in a private placement to Vertex Pharmaceuticals Incorporated, an existing investor. Total gross proceeds to Kymera, before deducting underwriting commissions and offering expenses, were approximately $213.3 million. • Announced multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies. Under the terms of the collaboration, signed in July 2..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy